 |
|
Screen-and-Treat Approaches for Cervical Cancer Prevention in Low-Resource Settings
A Randomized Controlled Trial
Lynette Denny, MD, PhD;
Louise Kuhn, PhD;
Michelle De Souza, MD;
Amy E. Pollack, MD, MPH;
William Dupree, MD;
Thomas C. Wright, Jr, MD
JAMA. 2005;294:2173-2181.
Context Non–cytology-based screen-and-treat approaches for cervical cancer prevention have been developed for low-resource settings, but few have directly addressed efficacy.
Objective To determine the safety and efficacy of 2 screen-and-treat approaches for cervical cancer prevention that were designed to be more resource-appropriate than conventional cytology-based screening programs.
Design, Setting, and Patients Randomized clinical trial of 6555 nonpregnant women, aged 35 to 65 years, recruited through community outreach and conducted between June 2000 and December 2002 at ambulatory women’s health clinics in Khayelitsha, South Africa.
Interventions All patients were screened using human papillomavirus (HPV) DNA testing and visual inspection with acetic acid (VIA). Women were subsequently randomized to 1 of 3 groups: cryotherapy if she had a positive HPV DNA test result; cryotherapy if she had a positive VIA test result; or to delayed evaluation.
Main Outcome Measures Biopsy-confirmed high-grade cervical cancer precursor lesions and cancer at 6 and 12 months in the HPV DNA and VIA groups compared with the delayed evaluation (control) group; complications after cryotherapy.
Results The prevalence of high-grade cervical intraepithelial neoplasia and cancer (CIN 2+) was significantly lower in the 2 screen-and-treat groups at 6 months after randomization than in the delayed evaluation group. At 6 months, CIN 2+ was diagnosed in 0.80% (95% confidence interval [CI], 0.40%-1.20%) of the women in the HPV DNA group and 2.23% (95% CI, 1.57%-2.89%) in the VIA group compared with 3.55% (95% CI, 2.71%-4.39%) in the delayed evaluation group (P<.001 and P = .02 for the HPV DNA and VIA groups, respectively). A subset of women underwent a second colposcopy 12 months after enrollment. At 12 months the cumulative detection of CIN 2+ among women in the HPV DNA group was 1.42% (95% CI, 0.88%-1.97%), 2.91% (95% CI, 2.12%-3.69%) in the VIA group, and 5.41% (95% CI, 4.32%-6.50%) in the delayed evaluation group. Although minor complaints, such as discharge and bleeding, were common after cryotherapy, major complications were rare.
Conclusion Both screen-and-treat approaches are safe and result in a lower prevalence of high-grade cervical cancer precursor lesions compared with delayed evaluation at both 6 and 12 months.
Trial Registration http://clinicaltrials.gov Identifier: NCT00233727.
Author Affiliations: Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa (Drs Denny and De Souza); Gertrude H. Sergievsky Center and Departments of Epidemiology (Dr Kuhn) and Pathology (Dr Wright), Columbia University, New York, NY; EngenderHealth, New York, NY (Dr Pollack); and HealthNetwork Laboratory, Allentown, Pa (Dr Dupree).
RELATED LETTERS
Prevention of Cervical Cancer in Low-Resource Settings
Imre Boncz
JAMA. 2006;295(11):1248.
EXTRACT
| FULL TEXT
Prevention of Cervical Cancer in Low-Resource Settings
Eric J. Suba, Kim R. Geisinger, Matthew A. Zarka, and Stephen S. Raab
JAMA. 2006;295(11):1248-1249.
EXTRACT
| FULL TEXT
Prevention of Cervical Cancer in Low-Resource Settings—Reply
Thomas C. Wright, Jr, Louise Kuhn, and Lynette Denny
JAMA. 2006;295(11):1249.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Feasibility of Management of High-Grade Cervical Lesions in a Single Visit: A Randomized Controlled Trial
Wendy R. Brewster, F. Allan Hubbell, Joan Largent, Argyrios Ziogas, Fritz Lin, Susan Howe, Theodore G. Ganiats, Hoda Anton-Culver, and Alberto Manetta
JAMA. 2005;294(17):2182-2187.
ABSTRACT
| FULL TEXT
A 21-Year-Old Woman With Atypical Squamous Cells of Undetermined Significance
George F. Sawaya
JAMA. 2005;294(17):2210-2218.
EXTRACT
| FULL TEXT
Cervical Cancer Prevention: Making Programs More Appropriate and Pragmatic
Paul D. Blumenthal and Lynne Gaffikin
JAMA. 2005;294(17):2225-2228.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women
Ogilvie et al.
CMAJ 2007;177:480-483.
ABSTRACT
| FULL TEXT
Agreement between Self- and Clinician-Collected Specimen Results for Detection and Typing of High-Risk Human Papillomavirus in Specimens from Women in Gugulethu, South Africa
Jones et al.
J. Clin. Microbiol. 2007;45:1679-1683.
ABSTRACT
| FULL TEXT
ALLIANCE FOR CERVICAL CANCER PREVENTION: SETTING THE RECORD STRAIGHT
Sherris et al.
Am. J. Public Health 2007;97:200-201.
FULL TEXT
Prospective study of hormonal contraception and women's risk of HIV infection in South Africa
Myer et al.
Int J Epidemiol 2007;36:166-174.
ABSTRACT
| FULL TEXT
An Armamentarium of Wart Treatments
Lipke
Clin Med Res 2006;4:273-293.
ABSTRACT
| FULL TEXT
Prevention of Cervical Cancer in Low-Resource Settings
Boncz
JAMA 2006;295:1248-1248.
FULL TEXT
Prevention of Cervical Cancer in Low-Resource Settings
Suba et al.
JAMA 2006;295:1248-1249.
FULL TEXT
Distinguishing the Temporal Association between Women's Intravaginal Practices and Risk of Human Immunodeficiency Virus Infection: A Prospective Study of South African Women
Myer et al.
Am J Epidemiol 2006;163:552-560.
ABSTRACT
| FULL TEXT
When to test women for human papillomavirus
Schiffman and Castle
BMJ 2006;332:61-62.
FULL TEXT
Alternative Strategies for Preventing Cervical Cancer
JWatch Women's Health 2006;2006:6-6.
FULL TEXT
Cervical Cancer Prevention: Making Programs More Appropriate and Pragmatic
Blumenthal and Gaffikin
JAMA 2005;294:2225-2228.
FULL TEXT
|
